- Previous Close
14.70 - Open
15.20 - Bid 14.40 x --
- Ask 14.90 x --
- Day's Range
14.10 - 15.20 - 52 Week Range
9.35 - 31.00 - Volume
46,863 - Avg. Volume
182,028 - Market Cap (intraday)
16.431M - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-0.03 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.00
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. It offers ImmunoINSIGHTS, an autoantibody profiling service that unlocks the immune system to discover and convert autoantibodies into actionable biomarkers; Sero Tag, a discovery engine which identifies relevant biomarker pool for target discovery or companion diagnostics; NavigAID, a creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. The company also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.
www.oncimmune.comRecent News: ONC.L
View MorePerformance Overview: ONC.L
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONC.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONC.L
View MoreValuation Measures
Market Cap
16.26M
Enterprise Value
20.61M
Trailing P/E
--
Forward P/E
72.99
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.89
Price/Book (mrq)
--
Enterprise Value/Revenue
16.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
586.08%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.21M
Net Income Avi to Common (ttm)
-3.14M
Diluted EPS (ttm)
-0.03
Balance Sheet and Cash Flow
Total Cash (mrq)
911k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--